Current Report Filing (8-k)
May 31 2017 - 01:53PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
May 22, 2017
PetLife
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-52445
|
|
33-1133537
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
38
West Main St., Hancock, MD
|
|
21750
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 473-8543
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01 Entry into a Material Definitive Agreement.
On
May 22, 2017, PetLife Pharmaceuticals, Inc. (“PetLife”) and Dr. Ralph T. Salvagno, Dr. Vivekananda Ramana, and Dr.
Baidvanath Mishra (collectively, Drs. Salvagno, Ramana and Mishra”), entered into an Assignment Agreement in regards to
the following:
|
●
|
On
March 31, 2017, a patent was filed for the treatment of cancer in pets, combining chlorotoxin and plant-based therapeutics.
The patent was filed in India titled
A Composition for Targeting Cancer in Canines and Humans
. The patent protection
is for both process and composition thus protecting not only the physical elements of the formulation but also the process
by which they are combined. This new patent pending advanced formulation will be the basis for PetLife’s product, Vitalzul™,
for the proposed treatment of certain cancers in dogs and cats. The human application will be addressed by management at a
later date.
|
|
|
|
|
●
|
On
May 9, 2017, the identical patent as filed in India, was filed with the United States Patent and Trademark Office.
|
The
Assignment Agreement between PetLife and Drs. Salvagno, Ramana and Mishra provided an irrevocable assignment of all rights of
the patent, which will be effected simultaneous with the issuance of each patent. Drs. Salvagno, Ramana and Mishra, in conjunction
with the assignment, will be reimbursed for all expenses related to developing the intellectual property used as a basis for the
patent, as well as other applicable expenses related to the patent.
Dr.
Ralph Salvagno is the Chief Executive Officer and a Director of PetLife. Dr. Ramana is the Chief Medical Officer of PetLife.
Item
9.01 Financial Statements and Exhibits.
The
exhibits listed in the following Exhibit Index are filed as part of this report:
Exhibit
No.
|
|
Description
|
|
|
|
10.6
|
|
Assignment
Agreement between PetLife Pharmaceuticals, Inc. and Dr. Ralph T. Salvagno dated May 22, 2017
|
|
|
|
10.7
|
|
Assignment
Agreement between PetLife Pharmaceuticals, Inc. and Dr. Vivekananda Ramana dated May 22, 2017
|
|
|
|
10.8
|
|
Assignment
Agreement between PetLife Pharmaceuticals, Inc. and Dr. Baidvanath Mishra dated May 22, 2017
|
|
|
|
99.1
|
|
Press
Release titled “PetLife Files for Patent for the Treatment of Cancer for Pets” as released on May 30, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
PETLIFE
PHARMACEUTICALS, INC.
(Registrant)
Dated:
May 31, 2017
|
By:
|
/s/
Ralph T. Salvagno, MD
|
|
|
Ralph
T. Salvagno, MD
|
|
|
Chief
Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Mar 2023 to Mar 2024